Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 17.80 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2022-03-30
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2015-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2015-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2015-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2015-03-31 was 25.14K shares, a 93.02% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2021 was 17.80K shares, a 94.81% decline from fiscal 2020.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2020 was 343.11K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2015 was 25.14K shares, a 98.78% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2014 was 2.06M shares, a 466.53% increase from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2021-12-31 | 17.80K shares 10-K · filed 2022-03-30 | |||
| 2020-12-31 | 343.11K shares 10-K · filed 2021-03-25 | |||
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | 0.00 shares derived: sum of 2 quarters · filed 2017-09-25 | 0.00 shares derived: sum of 3 quarters · filed 2017-09-25 | 25.14K shares 10-K · filed 2017-09-25 |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-01 | 0.00 shares derived: sum of 2 quarters · filed 2015-12-01 | 25.14K shares 10-Q · filed 2015-12-01 | 1.28M shares derived: sum of 4 quarters · filed 2017-06-19 |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | 25.14K shares 10-Q · filed 2015-08-19 | 1.28M shares derived: sum of 3 quarters · filed 2017-06-19 | 1.48M shares derived: sum of 4 quarters · filed 2017-06-19 |
| 2015-03-31 | 25.14K shares 10-Q · filed 2015-05-15 | 1.28M shares derived: sum of 2 quarters · filed 2017-06-19 | 1.48M shares derived: sum of 3 quarters · filed 2017-06-19 | 1.73M shares derived: sum of 4 quarters · filed 2017-06-19 |
| 2014-12-31 | 1.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | 1.45M shares derived: sum of 2 quarters · filed 2017-06-19 | 1.70M shares derived: sum of 3 quarters · filed 2017-06-19 | 2.06M shares 10-K · filed 2017-06-19 |
| 2014-09-30 | 193.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | 442.32K shares derived: sum of 2 quarters · filed 2014-11-13 | 802.32K shares 10-Q · filed 2014-11-13 | |
| 2014-06-30 | 249.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-19 | 609.32K shares 10-Q · filed 2014-08-19 | ||
| 2014-03-31 | 360.00K shares 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | 363.82K shares 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |